PTK2 and neoplasm: Taken together, these results support the conclusion that nuclear FAK enhances tumor resistance to cisplatin in vivo and that cisplatin sensitivity of FAK-NLS− tumors is associated with noncanonical ERK, JNK, and p38 MAPK activation.